Monthly Prescribing Reference

Corifact approved for treating congenital factor XIII deficiency

CSL Behring announced that Corifact (factor XIII concentrate [human] injection) has been approved for the routine prophylactic treatment of congenital factor XIII deficiency. Corifact is a ...
Monthly Prescribing Reference

Corifact Approved for Surgical Bleeding Management

CSL Behring announced that the FDA has approved an expansion of the indication for Corifact (Factor XIII concentrate [human]) infusion, to include the peri-operative management of surgical bleeding in ...
Medindia

CSL Behring Receives FDA Approval of Corifact for Treatment of Congenital Factor XIII Deficiency

First and only factor XIII concentrate approved in U.S. to treat extremely rare and potentially life-threatening bleeding disorder Congenital FXIII deficiency, also known as fibrin-stabilizing factor ...
Healio

FDA approves first treatment for Factor XIII deficiency

Please provide your email address to receive an email when new articles are posted on . The first product to prevent bleeding in people with congenital Factor XIII deficiency has been approved by the ...
Drug Store News

FDA OKs Corifact

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a rare bleeding disorder. The FDA announced the approval of Corifact, used to prevent bleeding in people with the ...
FierceBiotech

FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect

SILVER SPRING, Md., Feb. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare ...
Medindia

CSL Behring Receives FDA Approval to Expand the Indication for Corifact®

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency Congenital FXIII deficiency is a rare and ...